Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roivant Sciences Ltd
(NQ:
ROIV
)
11.88
+0.20 (+1.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roivant Sciences Ltd
< Previous
1
2
3
4
5
6
7
Next >
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
June 28, 2023
From
Roivant Sciences
Via
GlobeNewswire
Nasdaq, S&P 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results: Why This Analyst Rates Stocks 'Overweight' And Says 'Buy Weakness'
June 28, 2023
Via
Benzinga
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
June 28, 2023
From
Roivant Sciences
Via
GlobeNewswire
Why Roivant Sciences Stock is Trading Higher Today
June 22, 2023
Roivant Sciences Ltd (NASDAQ: ROIV) released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with
Via
Benzinga
A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout
June 22, 2023
The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis.
Via
Investor's Business Daily
5 Analysts Have This to Say About Roivant Sciences
June 08, 2023
Via
Benzinga
Why Shares of Roivant Sciences Jumped This Week
April 20, 2023
The company's stock benefited from another company's buyout.
Via
The Motley Fool
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
June 26, 2023
From
Roivant Sciences
Via
GlobeNewswire
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 22, 2023
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private...
Via
Benzinga
Analyst Expectations for Roivant Sciences's Future
March 16, 2023
Via
Benzinga
Why Roivant Sciences Stock Is Perking Up Today
June 22, 2023
Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock.
Via
The Motley Fool
Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday
June 22, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
June 22, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
June 21, 2023
From
Roivant Sciences
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023
June 08, 2023
Via
Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission
May 16, 2023
Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old...
Via
Benzinga
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
May 16, 2023
From
Roivant Sciences
Via
GlobeNewswire
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
April 23, 2023
Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so.
Via
The Motley Fool
These 2 Growth Stocks Might Be Incredibly Undervalued Right Now
April 20, 2023
These two biopharma stocks could be poised for a major growth spurt.
Via
The Motley Fool
EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis
April 17, 2023
While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up.
Via
Benzinga
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
April 17, 2023
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today.
Via
The Motley Fool
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
April 17, 2023
Merck is branching into immune-mediated diseases with this takeover.
Via
Investor's Business Daily
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
April 17, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93...
Via
Benzinga
Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
April 04, 2023
From
Lokavant
Via
Business Wire
Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
April 04, 2023
From
Lokavant
Via
Business Wire
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
March 29, 2023
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.
Via
InvestorPlace
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
March 28, 2023
From
Covant Therapeutics
Via
GlobeNewswire
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 21, 2023
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.
Via
Benzinga
Why Shares of Roivant Sciences Were Down Tuesday
March 21, 2023
After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.